Regeneron Pharmaceuticals Expects Its Q2 GAAP And Non-GAAP Financial Results Will Include A Pre-tax Charge Of ~$24M For Acquired In-process Research And Development, Impacting GAAP And Non-GAAP EPS By About $0.18 - 8K
Portfolio Pulse from Benzinga Newsdesk
Regeneron Pharmaceuticals expects its Q2 GAAP and Non-GAAP financial results to include a pre-tax charge of approximately $24 million for acquired in-process research and development. This will impact GAAP and Non-GAAP EPS by about $0.18.
July 08, 2024 | 11:22 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Regeneron Pharmaceuticals expects a $24 million pre-tax charge in Q2 for acquired in-process research and development, impacting GAAP and Non-GAAP EPS by $0.18.
The $24 million pre-tax charge for acquired in-process research and development will negatively impact Regeneron's Q2 GAAP and Non-GAAP EPS by $0.18. This could lead to a short-term decline in stock price as investors react to the lower earnings per share.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100